 Laurie Carr
Concepts (113)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Neoplasms | 10 | 2021 | 2526 | 1.390 |
Why?
| | Neuroendocrine Cells | 2 | 2016 | 32 | 0.950 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 2 | 2018 | 1040 | 0.650 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 4 | 2016 | 1081 | 0.550 |
Why?
| | Lung Diseases, Obstructive | 1 | 2016 | 50 | 0.500 |
Why?
| | Research Report | 1 | 2016 | 83 | 0.470 |
Why?
| | Medical Oncology | 1 | 2016 | 289 | 0.410 |
Why?
| | Antineoplastic Agents | 3 | 2013 | 2129 | 0.410 |
Why?
| | Octreotide | 1 | 2013 | 26 | 0.410 |
Why?
| | Early Detection of Cancer | 1 | 2018 | 447 | 0.400 |
Why?
| | Quinazolines | 1 | 2013 | 251 | 0.380 |
Why?
| | Lung Diseases | 2 | 2016 | 767 | 0.370 |
Why?
| | Neuroendocrine Tumors | 1 | 2013 | 116 | 0.360 |
Why?
| | Sirolimus | 1 | 2013 | 276 | 0.360 |
Why?
| | Iodine | 1 | 2010 | 27 | 0.340 |
Why?
| | Pyrazoles | 1 | 2013 | 423 | 0.330 |
Why?
| | Pyridines | 1 | 2013 | 506 | 0.320 |
Why?
| | Pyrroles | 1 | 2010 | 213 | 0.310 |
Why?
| | Lung | 4 | 2021 | 4060 | 0.300 |
Why?
| | Carcinoma | 1 | 2010 | 240 | 0.290 |
Why?
| | Delivery of Health Care | 1 | 2016 | 951 | 0.290 |
Why?
| | Immunosuppressive Agents | 1 | 2013 | 890 | 0.280 |
Why?
| | Electronic Health Records | 1 | 2016 | 1069 | 0.280 |
Why?
| | Loss of Heterozygosity | 1 | 2007 | 51 | 0.280 |
Why?
| | Indoles | 1 | 2010 | 412 | 0.270 |
Why?
| | Thyroid Neoplasms | 1 | 2010 | 343 | 0.250 |
Why?
| | Hyperplasia | 2 | 2016 | 175 | 0.230 |
Why?
| | Forced Expiratory Volume | 2 | 2018 | 531 | 0.230 |
Why?
| | Tomography, X-Ray Computed | 3 | 2019 | 2691 | 0.200 |
Why?
| | Solitary Pulmonary Nodule | 1 | 2021 | 22 | 0.170 |
Why?
| | Drug Resistance, Neoplasm | 2 | 2019 | 801 | 0.170 |
Why?
| | Proto-Oncogene Proteins c-yes | 1 | 2019 | 3 | 0.160 |
Why?
| | Dasatinib | 1 | 2019 | 54 | 0.160 |
Why?
| | Disease Progression | 2 | 2018 | 2757 | 0.160 |
Why?
| | Humans | 15 | 2021 | 137585 | 0.140 |
Why?
| | Aging | 1 | 2007 | 1864 | 0.130 |
Why?
| | Spirometry | 1 | 2018 | 281 | 0.130 |
Why?
| | Vital Capacity | 1 | 2018 | 311 | 0.130 |
Why?
| | Pleural Effusion, Malignant | 1 | 2016 | 12 | 0.130 |
Why?
| | Pleural Neoplasms | 1 | 2016 | 25 | 0.120 |
Why?
| | Peritoneal Neoplasms | 1 | 2016 | 93 | 0.120 |
Why?
| | Multiple Pulmonary Nodules | 1 | 2015 | 23 | 0.110 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2019 | 752 | 0.110 |
Why?
| | Neoplasm Staging | 3 | 2016 | 1389 | 0.110 |
Why?
| | Bronchiolitis | 1 | 2015 | 80 | 0.110 |
Why?
| | Machine Learning | 1 | 2019 | 493 | 0.110 |
Why?
| | Erlotinib Hydrochloride | 1 | 2013 | 72 | 0.100 |
Why?
| | Survival Rate | 1 | 2018 | 1972 | 0.100 |
Why?
| | Everolimus | 1 | 2013 | 91 | 0.100 |
Why?
| | Biopsy | 1 | 2016 | 1129 | 0.100 |
Why?
| | Follow-Up Studies | 2 | 2021 | 5131 | 0.100 |
Why?
| | Drug Administration Schedule | 2 | 2012 | 786 | 0.090 |
Why?
| | Registries | 2 | 2021 | 2035 | 0.090 |
Why?
| | Tomography, Spiral Computed | 1 | 2011 | 32 | 0.090 |
Why?
| | Biopsy, Needle | 1 | 2011 | 189 | 0.090 |
Why?
| | Epidermal Growth Factor | 1 | 2011 | 177 | 0.090 |
Why?
| | Incidence | 1 | 2018 | 2804 | 0.090 |
Why?
| | Tomography, Emission-Computed | 1 | 2010 | 66 | 0.090 |
Why?
| | Carcinoma, Medullary | 1 | 2010 | 17 | 0.080 |
Why?
| | Drug Therapy, Combination | 1 | 2013 | 1066 | 0.080 |
Why?
| | Aged, 80 and over | 3 | 2018 | 7635 | 0.080 |
Why?
| | Molecular Targeted Therapy | 1 | 2013 | 411 | 0.080 |
Why?
| | Bronchoscopy | 1 | 2011 | 223 | 0.080 |
Why?
| | Aged | 5 | 2021 | 23961 | 0.080 |
Why?
| | Case-Control Studies | 1 | 2018 | 3556 | 0.080 |
Why?
| | Chronic Disease | 1 | 2016 | 1793 | 0.080 |
Why?
| | Fluorodeoxyglucose F18 | 1 | 2010 | 135 | 0.080 |
Why?
| | Communication | 1 | 2016 | 879 | 0.080 |
Why?
| | Treatment Failure | 1 | 2010 | 356 | 0.080 |
Why?
| | Female | 7 | 2019 | 73304 | 0.080 |
Why?
| | Positron-Emission Tomography | 1 | 2010 | 294 | 0.080 |
Why?
| | Global Health | 1 | 2011 | 386 | 0.070 |
Why?
| | Biomarkers | 1 | 2019 | 4149 | 0.070 |
Why?
| | Neoplasm Metastasis | 1 | 2010 | 658 | 0.070 |
Why?
| | Occupational Exposure | 1 | 2011 | 341 | 0.070 |
Why?
| | United States | 2 | 2018 | 14841 | 0.070 |
Why?
| | Cell Proliferation | 1 | 2015 | 2475 | 0.070 |
Why?
| | Time Factors | 1 | 2018 | 6828 | 0.070 |
Why?
| | Middle Aged | 4 | 2019 | 33479 | 0.060 |
Why?
| | Male | 6 | 2019 | 67762 | 0.060 |
Why?
| | Comorbidity | 1 | 2011 | 1622 | 0.060 |
Why?
| | Cellular Senescence | 1 | 2007 | 189 | 0.060 |
Why?
| | DNA Repair | 1 | 2007 | 231 | 0.060 |
Why?
| | DNA Damage | 1 | 2007 | 420 | 0.060 |
Why?
| | Adult | 4 | 2019 | 37929 | 0.060 |
Why?
| | Mutation | 2 | 2016 | 3958 | 0.060 |
Why?
| | Risk Factors | 1 | 2018 | 10388 | 0.050 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2012 | 1692 | 0.050 |
Why?
| | Cell Differentiation | 1 | 2010 | 1991 | 0.050 |
Why?
| | Infant | 1 | 2016 | 9465 | 0.050 |
Why?
| | Patient Identification Systems | 1 | 2021 | 16 | 0.040 |
Why?
| | Retrospective Studies | 2 | 2016 | 15657 | 0.040 |
Why?
| | Incidental Findings | 1 | 2021 | 87 | 0.040 |
Why?
| | Reference Standards | 1 | 2019 | 186 | 0.040 |
Why?
| | Oncogenes | 1 | 2016 | 116 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 2019 | 1483 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2016 | 686 | 0.030 |
Why?
| | Receptors, Platelet-Derived Growth Factor | 1 | 2012 | 15 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-sis | 1 | 2012 | 39 | 0.020 |
Why?
| | Imatinib Mesylate | 1 | 2012 | 79 | 0.020 |
Why?
| | Neutropenia | 1 | 2012 | 146 | 0.020 |
Why?
| | Remission Induction | 1 | 2012 | 288 | 0.020 |
Why?
| | Benzamides | 1 | 2012 | 216 | 0.020 |
Why?
| | Frail Elderly | 1 | 2012 | 131 | 0.020 |
Why?
| | Paclitaxel | 1 | 2012 | 230 | 0.020 |
Why?
| | Fatigue | 1 | 2012 | 329 | 0.020 |
Why?
| | Piperazines | 1 | 2012 | 350 | 0.020 |
Why?
| | Survival Analysis | 1 | 2012 | 1325 | 0.020 |
Why?
| | Pyrimidines | 1 | 2012 | 470 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2012 | 2057 | 0.020 |
Why?
| | Animals | 1 | 2007 | 36940 | 0.010 |
Why?
| | Signal Transduction | 1 | 2012 | 5079 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2012 | 10811 | 0.010 |
Why?
|
|
Carr's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|